Related Experiment Video
Updated: Jun 29, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Integrin agonists as adjuvants in chemotherapy for melanoma
Martin A Schwartz1, Kevin McRoberts, Matthew Coyner
1Department of Microbiology, Robert M. Berne Cardiovascular Research Center, University of Virginia, 415 Lane Road, Charlottesville, VA 22908, USA. maschwartz@virginia.edu
Purpose:
Metastatic melanomas are generally resistant to chemotherapy and radiation, even when wild-type for p53. These tumors often grow in small nests where many of the cells have little contact with extracellular matrix (ECM). Previous work showed that M21 melanomas undergo apoptosis in response to chemotherapy when cells are adherent to ECM but not in suspension. Thus, reduced integrin-dependent adhesion to ECM could mediate therapy resistance. The goal of this study was to test whether stimulation of integrin signaling could increase chemotherapeutic efficacy.
Experimental Design:
Colony forming assays and survival assays were used to test the responses of melanoma lines in vitro. Severe combined immunodeficient mice with subcutaneous human melanomas received chemotherapy with or without reagents that stimulate integrin signaling; tumor volume was then monitored over time.
Results:
Clonal growth assays confirmed that M21 cells showed reduced sensitivity to the chemotherapeutic drug 1-beta-D-arabinofuranosylcytosine (araC). When five additional primary melanoma lines were screened, 80% showed higher sensitivity when adherent compared with suspended. Subcutaneous M21 tumors in vivo showed minimal ECM between tumor cells. To evaluate the importance of integrin signaling in chemoresistance in this model, mice were treated with araC, with or without the multivalent snake venom disintegrin contortrostatin or the activating anti-beta1 integrin antibody TS2/16. Although araC, TS2/16, or contortrostatin alone had little effect on M21 tumor growth, combining araC with either integrin signaling reagents strongly reduced growth (P = 0001).
Conclusions:
Loss of integrin-mediated adhesion is rate limiting for therapeutic response in this model. Combining chemotherapy with reagents that stimulate integrin signaling may therefore provide a new approach to therapy.
Insights
Stimulating integrin signaling enhances chemotherapy effectiveness in melanoma. Combining chemotherapy with integrin-activating agents significantly reduced tumor growth in preclinical models, offering a novel therapeutic strategy for resistant melanomas.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Metastatic melanomas often exhibit resistance to conventional therapies like chemotherapy and radiation.
- Tumor cells in small nests may have reduced contact with the extracellular matrix (ECM), potentially contributing to therapy resistance.
- Previous studies indicated that M21 melanomas are sensitive to chemotherapy when adherent to ECM but resistant in suspension, suggesting a role for integrin-dependent adhesion.
Purpose of the Study:
- To investigate whether stimulating integrin signaling can enhance the efficacy of chemotherapy in melanoma.
- To determine if targeting integrin-mediated adhesion can overcome chemoresistance in metastatic melanoma models.
Main Methods:
- In vitro colony forming and survival assays were performed on melanoma cell lines.
- Severe combined immunodeficient mice bearing subcutaneous human melanomas were treated with chemotherapy (1-beta-D-arabinofuranosylcytosine, araC).
- Mice received araC in combination with reagents that stimulate integrin signaling, such as contortrostatin or the anti-beta1 integrin antibody TS2/16, with tumor volume monitored.
Main Results:
- M21 melanoma cells demonstrated reduced sensitivity to araC in vitro.
- Eighty percent of five additional melanoma lines screened showed increased sensitivity when adherent compared to suspended.
- Combination therapy of araC with either contortrostatin or TS2/16 significantly reduced M21 tumor growth in vivo (P = 0.001), whereas single agents had minimal effect.
Conclusions:
- Loss of integrin-mediated adhesion appears to be a critical factor limiting therapeutic response in this melanoma model.
- Combining standard chemotherapy with agents that stimulate integrin signaling represents a promising new therapeutic approach for treating resistant melanomas.
Related Concept Videos
01:27Tumor Immunotherapy
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:15Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
01:17Intracellular Signaling Affects Focal Adhesions
Some...
01:10Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...